ArticleMaterials today. Bio2025
Homologous targeted neutrophils-liposome system for pyroptosis-enhanced antitumor immunotherapy of triple-negative breast cancer.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gasdermin E: Bridging Pyroptosis, Immunity, and Disease Pathogenesis Toward Precision Intervention.The protein journal · 2026Review
- Targeting the tripartite axis of immune-metabolic-spatial crosstalk to overcome therapy resistance in breast cancer.Frontiers in immunology · 2026Review
- GSDME in cardiovascular diseases: research system and contemporary progress.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC), characterized by negative expression of estrogen receptor, progesterone receptor, and oncogene HER-2, always exhibits resistance to targeted drugs. Immunotherapies have demonstrated promising clinical responses and significant potential for TNBC treatment. Enhancing and activating antitumoral immunity can help restrain TNBC progression. In this work, we developed and validated an irradiation-responsive, tumor-targeting, and pyroptosis-enhanced drug delivery system based on neutrophils for effective TNBC treatment. Specifically, TNBC cell membrane-derived liposomes were loaded with photothermal agent IR775 and a pyroptosis-promoting plasmid carrying GSDME coding sequence (GI-LNPs). These GI-LNPs were then anchored onto the surface of neutrophils via biotin-avidin interaction and delivered into the tumor through local injury-driven neutrophil infiltration. Compared to conventional therapeutic strategies, NE-GI-LNPs accumulated and penetrated more deeply into tumor tissues. Furthermore, IR775-triggered the generation of caspase-3 under NIR laser irradiation promoted the cleavage of expressed GSDME, converting apoptosis to pyroptosis in 4T1 cells and enhancing antitumor immunity. Overall, our study demonstrated that multifunctional GI-LNPs delivered by neutrophils could effectively inhibit tumor growth through pyroptosis-enhanced antitumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.